QuantumLeap Healthcare Collaborative
Quick facts
Marketed products
- Pertuzumab and Trastuzumab · Oncology
Pertuzumab and trastuzumab are monoclonal antibodies that block HER2 signaling in cancer cells by binding to different epitopes of the HER2 receptor, preventing tumor growth and survival.
Phase 2 pipeline
- ALX148
- AMG 386 and Trastuzumab · Oncology
AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing it from interacting with its receptor, thereby inhibiting angiogenesis. Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in certain cancer cells. - AMG 386 with or without Trastuzumab · Oncology
AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis. - Cemiplimab plus REGN3767 · Oncology
Cemiplimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhancing T-cell activation and immune response against tumor cells. - Durvalumab plus Olaparib · Oncology
PD-1 inhibitor - GSK 5733584
- MK-2206 with or without Trastuzumab
- Patritumab and Trastuzumab
- Pembrolizumab - 4 cycle
- Pembrolizumab - 8 cycle · Oncology
PD-1 inhibitor - T-DM1 and Pertuzumab
- Talazoparib plus Irinotecan
- Tucatinib plus trastuzumab and pertuzumab
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: